Toxicology services

Specialist chemical pathologists and toxicologists are available for consultation to assist with the understanding and interpretation of reports.

For further information on services please contact Stephen Hawkins on (02) 9855 5368 or email.

  • Assay integrity is maintained through the regular assay of quality control material.

  • Participation in external quality assurance programmes ensures the proficiency of staff and equipment.

  • In the event of results being challenged, a secondary referee specimen, with security seals intact, shall be made available for testing with the consent of the donor. 

  • All samples are stored in a monitored secure refrigerated area.

  • Negative samples are stored for 1 month. Positive samples are stored for 3 months. Donor, GP and Clinic samples are stored for 1 month.

Douglass Hanly Moir Pathology (DHM) is committed to ensuring the privacy and confidentiality of personal information. Our company complies with the Privacy Act 1988 (Cth) (Privacy Act), the associated Australian Privacy Principles (APPs) and state or territory legislation that governs how private sector health service providers should handle personal information, including, but not limited to, health information.

What types of information do we collect and hold?

The type of personal information we collect depends on who you are, our relationship with you and the nature of our interaction with you. It will include only the information that is: 

  • Reasonably necessary for us to engage with you in the usual course of our business 
  • Necessary to provide you with services (including, in the case of patients, coordinating and communicating with your healthcare providers) 
  • Required for administrative and internal business purposes related to the services we provide to you 

Please click here to view our privacy policy.

The drug detection time is the time from the last dose of the drug until a negative screening result is obtained using the cut-off levels in the table under 'Reporting levels'. Detection times vary with different drugs and different individuals and according to the amount and frequency of drug taken. It is important to note that whilst a drug may be excreted in the urine for a significant time, it may not reach the threshold required for a positive result.

The following table lists the average detection times for a number of drugs.

Drug class

Detection time (days)


  • 1-2 joints
  • Oral ingestion
  • Moderate use (4/week)
  • Heavy use (daily)
  • Chronic use(>5 joints /day)









Benzodiazepines (therapeutic)



<24 hours


Note: Individual variation can significantly influence the detection time of pharmacological agents in urine specimens

A confirmed positive result reveals the presence of a drug in the specimen at or above the 'cut-off' level. It gives no information about how or when the drug was taken. It also does not provide an indication of impairment. A positive result may relate to previous drug use with no current physical effects. Positive results are reported as 'Positive', while a negative result is reported as 'Negative'.

The initial test is a screening test which identifies a range of illicit and therapeutic substances. Screening is performed by immunoassay on the Olympus AU2700 using Cedia reagents and methodology. Routine screening involves the testing of the following classes:

  • Opiates e.g. heroin, morphine
  • Amphetamine type substances e.g. speed, ecstasy
  • Cannabis metabolites
  • Cocaine metabolites
  • Benzodiazepines eg tranquillisers, sedatives

Testing can also be performed for additional drugs, including alcohol, methadone and buprenorphineIf the initial screening test is positive, a second unopened sample aliquotted from the original specimen is tested by a different method for confirmation of the initial result. Confirmation of drug classes detected by immunoassay is performed by mass spectrometry . The presence of each drug or metabolite is tested for at or above a predefined cut-off level (see 'Reporting levels' below). These levels are dictated by International Standards for urine drug testing and defined in the AS/NZS 4308:2008 standard. The cut-off levels are established because the aim of workplace testing is usually to identify significant residues of the targeted drug, not minute traces. For a result to be 'positive', the amount of the drug detected must be at or above the cut-off level. If a drug is detected but the level is below the "cut-off" the result will be negative. The cut-off levels for some classes differ for screening and confirmation. This is due to the non-specific nature of the screening assay versus the highly specific nature of the GC/MS confirmation.

Onsite testing of urine samples offers a preliminary test result. Specimens are collected as outlined in the preceding sections and tested in individual testing kits usually for the five major classes of drugs. Positive on site screening results must be sent to the laboratory for screening by immunoassay and, if necessary, confirmation by mass spectrometry. Onsite screening provides a rapid method for excluding the presence of drugs but, due to the lack of specificity of onsite kits, it does not provide a dependable positive result. DHM Toxicology Department recommends regular quality control checks on negative results by correlation with the laboratory immunoassay screen. 

Analyte Reporting level immunoassay screening test (ug/L) Reporting level mass spectrometry confirmatory test (ug/L)

Cannabis metabolites




Amphetamine-type substances

  • Amphetamine
  • Methylamphetamine
  • MDMA
  • Phentermine
  • Pseudoephidrine
  • Ephedrine
  • MDA




  • Codeine
  • Morphine
  • 6-monoacetylmorphine




Cocaine metabolites

  • Ecgonine methylester
  • Benzoylecgonine





  • Oxazepam
  • Temazepam
  • Diazepam
  • Notdiazepam
  • 7-amino-clonazepam
  • 7-amino-flunitrazepam
  • 7-amino-nitrazepam
  • α-hydroxy-alprazolam



DHM's Toxicology Department distributes a combined request and chain-of-custody form.

This enables all the client details and the tracking of the specimen to be recorded on the one form. It is important to complete the form fully and correctly. Ensure that the client's full name, date of birth and date of collection are recorded on the form. Details such as medication which the client may be taking are important in interpreting the results of the urine drug test. It is therefore necessary in interpreting results to be aware of therapeutic drugs which the client may be taking.

  • Accreditation to AS/NZS 4308:2008. Compliant with ISO/IEC 17025:2005ISO 15189:2007 
  • Strict chain-of-custody maintained at all times from supervised collection of the specimen through to secure storage following reporting of results
  • Specifically designated collection centres suitable for supervised collection of urine specimens for drug testing
  • Qualified staff trained in collection procedures compliant with AS/NZS 4308:2008
  • Tamper-evident collection kits & transport satchels
  • Secure Laboratory Facility
  • Accredited Screening and Confirmatory Testing Procedures
  • Screening performed by immunoassay in compliance with AS/NZS 4308:2008 cut-off levels
  • Creatinine measurement routinely performed as an additional check of specimen integrity
  • Positive screening results confirmed by Mass Spectrometry in compliance with AS/NZS 4308:2008 cut-off levels

Depending on time of arrival in the laboratory, samples are processed for screening either the same day or the morning after arrival in the laboratory. Hence negative screening results are available within 24 hours of the specimen arriving in the laboratory.

Positive results are available within 48 hours of arrival in the laboratory (confirmation of 1 class). Second and further classes may take longer to analyse.